OTLKOutlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an o…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement. | ||
 Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet Outlook Therapeutics stock has been through a very rough stretch over the past few years, and the current checks suggest it still does not screen as a clear bargain despite the recent approval and upcoming launch plans for LYTENAVA. Over the last 5 years, Outlook Therapeutics has delivered a share price decline of about 98%, which shows how much long term holders have seen their investment erode. The planned U.S. commercial launch of FDA approved LYTENAVA, funded in part by a roughly US$55m... | ||
 Oncobiologics Q3 Earnings Call Highlights Oncobiologics (NASDAQ:OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United | ||
 Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary Moby summary of Outlook Therapeutics, Inc.'s Q3 2026 earnings call | ||
 Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Why Did OTLK Stock Crash In Pre-Market Today? Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday. | ||
 OTLK Up More Than 300% in 3 Months: Here's What You Should Know Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end. | ||
 iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +5,900.00% and +2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 Outlook Therapeutics to Report Q3 Earnings: What's in the Cards? OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval. | ||
 Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates Twist Bioscience (TWST) delivered earnings and revenue surprises of -12.00% and +3.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Outlook Therapeutics (OTLK) Is Down 24.3% After Landmark FDA Wet AMD Drug Approval - Has The Bull Case Changed? Outlook Therapeutics previously announced that the FDA approved LYTENAVA (bevacizumab-vikg) for neovascular (wet) age-related macular degeneration, making it the first and only FDA-approved ophthalmic bevacizumab for this condition in the United States. An interesting aspect of this approval is Outlook’s expectation of 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act, in a US anti-VEGF retina market estimated at about US$8.50 billion... | ||
Outlook Therapeutics (OTLK) Wins FDA Approval, Is The Valuation Already Priced In? Outlook Therapeutics (OTLK) has received U.S. Food and Drug Administration approval for LYTENAVA, the first ophthalmic bevacizumab formulation cleared for treating neovascular age related macular degeneration. This approval places the company directly in the large U.S. anti VEGF retina market. See our latest analysis for Outlook Therapeutics. Despite FDA approval and a recent broker upgrade, Outlook Therapeutics’ recent share price return has been volatile. The stock is down 15% over the past... | ||
 Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.’s ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The regulatory milestone distinguishes LYTENAVA as the inaugural and sole FDA-approved ophthalmic... | ||
Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG BTIG upgraded the stock to ‘Buy’ from ‘Neutral’ after Outlook Therapeutics received regulatory approval for its wet AMD therapy. | ||
 Outlook Therapeutics wins FDA approval for Lytenava in wet AMD Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD. | ||
 Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD Outlook Therapeutics (NASDAQ:OTLK) shares rose approximately 8. 9% in pre-market trading as investors continued to react positively to the U. | ||
 FDA scientists question Capricor data; Legend CEO steps down Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble. | ||
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside Outlook expects a U.S. launch before year-end and anticipates 12 years of market exclusivity. | ||
 FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight. | ||
OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab LYTENAVA is now the first and only FDA-approved version of the drug bevacizumab specifically made for injection into the eye to treat wet age-related macular degeneration. | ||
OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’ After two rejections, retail investors are hopeful the FDA will approve Outlook Therapeutics’ Lytenava for the treatment of wet AMD. | ||
 Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA Outlook Therapeutics, Inc. (NASDAQ:OTLK) is one of the 10 High Growth Stocks Insiders Are Buying. On June 16, 2026, Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced that the U.S. Food and Drug Administration acknowledged receipt of the resubmission of the Biologics License Application for ONS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration, or wet AMD. The […] | IInsider Monkey | |